drugset / Trial / NCT06714955
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
Timeline
- Start
- 2024-10-21
- Primary completion
- 2025-01-21
- Completion
- 2025-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGM0504 | Unknown | 10 mg | Subcutaneous |
| Subject | BGM0504 | Unknown | 15 mg | Subcutaneous |
Indications
No indication recorded.